This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Italian antitrust probe into Byooviz drugmakers pushed back to October

( April 8, 2026, 07:59 GMT | Official Statement) -- MLex Summary: The Italian competition authority has said that its investigation into several drugmakers — to see if they coordinated commercial strategies to delay the market entry of eye-disease treatment Byooviz — will now wrap up in mid-October. The probe, which began in 2024, had been set to conclude by the end of March. The drugmakers under investigation include Samsung Bioepis, Novartis and Biogen. Byooviz is a biosimilar drug based on the active ingredient ranibizumab.The notice follows (in Italian). ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections